Figure 7
Figure 7. Rates of fibrinogen (Fgn) loss and fibrin degradation product (FDP) production are enhanced in both lethal (LDEC) and sublethal (SLEC) doses of E coli by the mAbTAFI/TM#16. (A) In a representative animal that received a LDEC, Fgn loss (■, □) and FDP production (●, ○) in the absence of mAbTAFI/TM#16 (■, ●) occur slowly compared with in the presence of the mAbTAFI/TM#16 (□, ○). (B) After receiving a SLEC, Fgn loss (■) occurs slowly and FDP production (●) does not increase in the absence of mAbTAFI/TM#16; however in the presence of mAbTAFI/TM#16, both Fgn loss (□) and FDP production (○) were observed.

Rates of fibrinogen (Fgn) loss and fibrin degradation product (FDP) production are enhanced in both lethal (LDEC) and sublethal (SLEC) doses of E coli by the mAbTAFI/TM#16. (A) In a representative animal that received a LDEC, Fgn loss (■, □) and FDP production (●, ○) in the absence of mAbTAFI/TM#16 (■, ●) occur slowly compared with in the presence of the mAbTAFI/TM#16 (□, ○). (B) After receiving a SLEC, Fgn loss (■) occurs slowly and FDP production (●) does not increase in the absence of mAbTAFI/TM#16; however in the presence of mAbTAFI/TM#16, both Fgn loss (□) and FDP production (○) were observed.

Close Modal

or Create an Account

Close Modal
Close Modal